Research programme: tyrosine kinase inhibitors - Ocular Therapeutix

Drug Profile

Research programme: tyrosine kinase inhibitors - Ocular Therapeutix

Alternative Names: OTX-TKI

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Ocular Therapeutix
  • Class Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 09 May 2017 Pharmacodynamics data from a preclinical trial in Wet age-related macular degeneration released by Ocular Therapeutix
  • 10 Mar 2017 Preclinical trials in Diabetic macular oedema in USA (Intravitreous)
  • 10 Mar 2017 Preclinical trials in Retinal vein occlusion in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top